Combination Therapy for COPD Offers No Survival Benefit
An editorialist writes that although the combination therapy results are difficult to interpret, "monotherapy with corticosteroids should not be advocated for patients with COPD," while "monotherapy with a long-acting bronchodilator appears to be safe."

So



Combination therapy with a long-acting beta-agonist plus a corticosteroid offers some benefits for COPD patients, but not survival benefits, according to a study in today's New England Journal of Medicine.